Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q1 2021 Earnings Presentation
29 slides from Marinomed Biotech's earnings presentation, May 26, 2021
Slide 1: Solving the unsolvable with radical innovation
Solving the unsolvable with radical innovation Presentation 26th May 2021 Andreas Grassauer, CEO, Pascal Schmidt, CFO
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Content
Content 1. Highlights 2. Market 3. R&D progress/pipeline 4. Financials 5. Outlook 3
Slide 4: Q1 Highlights
Q1 Highlights Key achievements +119% February Revenues increased to - Publication in peer-reviewed journal by Friedrich €2.2m from €1.0m in Alexander University Erlangen previous years first quarter - Publication of independent Argentinian research group on positive clinical data with Carragelose ®
Slide 5: Content
Content 1. Highlights 2. Market 3. R&D progress/pipeline 4. Financials 5. Outlook 5
Slide 6: Snapshot on business drivers
Snapshot on business drivers 1. Accelerated vaccination process increases reason to believe “normal” life and business activities may return soon 2. The corona virus pandemic is slowly, but steadily moving towards becoming endemic 3. Clinical and non-clinical data allows negotiations with more power
Slide 7: Content
Content 1. Highlights 2. Market 3. R&D progress/pipeline 4. Financials 5. Outlook 7
Slide 8: Marinomed Pipeline: Carragelose
Marinomed Pipeline Carragelose® 8
Slide 9: Carragelose neutralizes SARS-CoV-2 in vitro
Carragelose® neutralizes SARS-CoV-2 in vitro Recently published data together with the Friedrich Alexander University in Erlangen, Institute of Virology Carragelose® blocks viral replication at concentrations as low as 5µg/ml. Source: PLOS ONE | https://doi.org/10.1371/journal.pone.0237480 FAU Erlan
Slide 10: SARS-CoV-2 prophylaxis trial in health care professionals with iota-carrageenan
SARS-CoV-2 prophylaxis trial in health care professionals with iota-carrageenan Clinical trial completed ▪ Source: https://www.clinicaltrials.gov/ct2/show/NCT04521322 Study CARR-CoV-02 https://milstein.conicet.gov.ar/la-eficacia-del-spray-nasal-con-carragenina-para-la-prevencion-del- Location covid-
Slide 11: Ongoing SARS-CoV-2 clinical trials with iota-carrageenan
Ongoing SARS-CoV-2 clinical trials with iota-carrageenan One co-sponsored to own clinical studies Study ICE-COVID CHC-20-04 CIA-20-03 Location Swansea, UK Vienna, Austria Vienna, Austria Estimate Enrollment 480 participants 334 participants 330 patients Purpose Prevention Prevention Treatment Medica
Slide 12: SARS-CoV-2 and its variants will stay with us
SARS-CoV-2 and its variants will stay with us The virus and its mutants emerge globally Brasil Cambodia Czech Rep. Paraquay Senegal Indonesia Sweden Srilanka England Slowakia Australia Italy USA Turkey Quelle: www.nextstrain.org 12
Slide 13: Carragelose – Clinically validated for the prevention of COVID-19
Carragelose® – Clinically validated for the prevention of COVID-19 Side effect free option for COVID-19 prevention ▪ Further clinical trials in Austria and UK are recruiting – vaccination might influence the outcome – further trials in preparation including an inhalation trial ▪ A trial has been ini
Slide 14: Carragelose Products
Carragelose® Products Protection from COVID-19 and common cold is available in stores next to you Example of Carragelose® based nasal sprays Available in more than 40 countries Sources: Company Data
Slide 15: Marinomed Pipeline: Marinosolv
Marinomed Pipeline Marinosolv® 15
Slide 16: Marinosolv development status
Marinosolv® development status Advanced pipeline of Marinosolv®-enabled compounds 3 Ophthalmology Tacrosolv in allergic conjunctivitis 1 Nose phase II in 2021* Budesolv in allergic rhinitis Tacrosolv in dry eye disease phase III exp. in 2022* phase III completed, preparing registration Flutisolv Oth
Slide 17: Budesolv and Flutisolv target the dynamic Allergic Rhinitis market
Budesolv and Flutisolv target the dynamic Allergic Rhinitis (AR) market Intranasal corticosteroid market share increasing 1,2 Intranasal corticosteroid market share increasing1,2 7% 3% 38% 15% 47% 12% 2019 2028 USD USD 13.0bn 17.4bn 43% 35% corticosteroids antihistamines immunotherapy other ▪ Standa
Slide 18: Phase II clinical trial for Tacrosolv in allergic conjunctivitis
Phase II clinical trial for Tacrosolv in allergic conjunctivitis Therapeutic Effect of Tacrosolv in Patients with Allergic Study Rhinoconjunctivitis Location Austria, Vienna Challenge Chamber Enrollment 64 participants Design Challenge trial, double blind, placebo-controlled, randomized, cross over
Slide 19: Tacrosolv – potential game changer in the treatment of inflammatory eye diseases
Tacrosolv – potential game changer in the treatment of inflammatory eye diseases Tacrosolv is a potential game changer in the treatment of inflammatory eye diseases because: ▪ Tacrolimus is 100 times more effective than cyclosporine and is better bioavailable when solubilized with Marinosolv® ▪ 34 m
Slide 20: Content
Content 1. Highlights 2. Market 3. R&D progress/pipeline 4. Financials 5. Outlook 20
Slide 21: Significant year-over-year growth also for Q1
Significant year-over-year growth also for Q1 Solid growth path of Carragelose ® Y-o-Y comparison of Revenues (in m€) Margin Q1 2021 Q1 2020 Sale of goods 2.1 0.9 4.0 +59% * Cost of goods sold (1.3) (0.7) +68% Gross result 0.8 0.2 3.1 2.8 2.8 +119% Gross margin 37.8% 24.8% 2.2 +40% 2.0 Market develo
Slide 22: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) €m Q1 2021 Q1 2020 1 Revenue €m Q1 2021 Q1 2020 Sale of goods 2.1 0.9 Revenues 1 2.2 1.0 License revenues 0.1 0.1 Other income 2 0.5 0.1 Other revenues 0.0 0.0 Other net gains/losses 0.0 (0.0) Total revenue 2.2 1.0 Materials expenses 3 (1.4) (0.7) 2 Increase in res
Slide 23: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q1 2021 2020 1 Includes fully recognized headquarter (incl. land Assets and building) (€5.7m) Intangible assets 2.0 2.1 2 Inventories €m Q1 2021 2020 Property, plant and equipment 1 6.5 6.0 Goods for sale 0.3 0.1 Deposits and other non-current 0.0 0.0
Slide 24: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q1 2021 2020 1 Primarily related to first and second tranche of EIB loan (€9.0m) and ERP/aws real estate refinancing Equity and liabilities (€3.0m) Share capital 1.5 1.5 2 Decrease related to reduced prefinancing of Capital reserves 41
Slide 25: Content
Content 1. Highlights 2. Market 3. R&D progress/pipeline 4. Financials 5. Outlook 25
Slide 26: Strong development, however, with uncertainty in timing
Strong development, however, with uncertainty in timing Both Marinosolv® and Carragelose® continue to be strong value drivers ▪ SARS-CoV-2 will stay a predominant topic and affect Marinomed’s development ▪ Carragelose® revenues to further increase but at lower pace than in 2020 ▪ Focus on clinical s
Slide 27: Stay Healthy!
Stay Healthy! …and further reduce the risk by following these rules + + + Wash Keep Wear Use your hands distance a mask Carragelose® regularly products 27
Slide 28: www.marinomed.com
: Orrarino www.marinomed.com : ie
Slide 29: Investor Relations Contact
Investor Relations Contact Pascal Schmidt CFO phone: +43 2262 90300 e-mail: IR@marinomed.com Financial Calendar 29